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This study examined the pathological complete response (pCR) rate and safety of sequential gemcitabine-based combinations in
breast cancer. We also examined gene expression profiles from tumour biopsies to identify biomarkers predictive of response. Indian
women with large or locally advanced breast cancer received 4 cycles of gemcitabine 1200mgm
 2 plus doxorubicin 60mgm
 2
(GemþDox), then 4 cycles of gemcitabine 1000mgm
 2 plus cisplatin 70mgm
 2 (GemþCis), and surgery. Three alternate dosing
sequences were used during cycle 1 to examine dynamic changes in molecular profiles. Of 65 women treated, 13 (24.5% of 53
patients with surgery) had a pCR and 22 (33.8%) had a complete clinical response. Patients administered Gem d1, 8 and Dox d2 in
cycle 1 (20 of 65) reported more toxicities, with G3/4 neutropenic infection/febrile neutropenia (7 of 20) as the most common cycle-
1 event. Four drug-related deaths occurred. In 46 of 65 patients, 10-fold cross validated supervised analyses identified gene
expression patterns that predicted with X73% accuracy (1) clinical complete response after eight cycles, (2) overall clinical complete
response, and (3) pCR. This regimen shows strong activity. Patients receiving Gem d1, 8 and Dox d2 experienced unacceptable
toxicity, whereas patients on other sequences had manageable safety profiles. Gene expression patterns may predict benefit from
gemcitabine-containing neoadjuvant therapy.
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Although the effectiveness of neoadjuvant chemotherapy vs
adjuvant chemotherapy in locally advanced breast cancer remains
controversial (Este ´vez and Gradishar, 2004; Cianfrocca and
Gradishar, 2005), general findings indicate that both approaches
result in equivalent disease-free survival and overall survival
(Scholl et al, 1994; Fisher et al, 1998; van der Hage et al, 2001).
Clinical trial results indicate that 60–80% of women who receive
neoadjuvant chemotherapy have a clinical response, and 10–20%
achieve a pathological complete response (pCR) (Cianfrocca and
Gradishar, 2005). Because pCR predicts long-term survival (Fisher
et al, 1998; Kuerer et al, 1999; Wolmark et al, 2001), ongoing
research is focused on identifying regimens that improve the pCR
rate and on identifying biomarkers that can predict response to
neoadjuvant chemotherapy.
Anthracycline-based regimens are efficacious and widely used in
neoadjuvant breast cancer therapy, but debate remains as to which
combinations provide encouraging activity balanced by an
acceptable safety profile. Gemcitabine has demonstrated single-
agent activity in breast cancer (Heinemann, 2003), and is indicated
as first-line therapy in combination with paclitaxel for patients
with metastatic breast cancer after failure of prior anthracycline-
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scontaining adjuvant chemotherapy (Albain et al, 2004). In the
neoadjuvant setting, gemcitabine has been combined with
anthracyclines and/or taxanes in several phase II studies of locally
advanced breast cancer, with clinical response rates and pCR rates
ranging from 71–95% and 3–26%, respectively (Gomez et al, 2001;
Silva et al, 2002; Este ´vez et al, 2004; Schneeweiss et al, 2004).
Gemcitabine plus cisplatin (GemþCis) combination therapy
has also shown activity in metastatic or refractory breast cancer,
with response rates from 26–50% (Heinemann, 2002). Given the
tumour shrinking capability of the combination of gemcitabine
and doxorubicin (GemþDox) (Pe ´rez-Manga et al, 2000; Gomez
et al, 2001), we hypothesised that additional cycles of combination
chemotherapy may improve pCR rates. In this phase II study, we
evaluated two combination regimens administered sequentially as
neoadjuvant chemotherapy in Indian women with operable breast
cancer: four cycles of GemþDox followed by four cycles of
GemþCis.
Administering chemotherapy prior to surgical resection provides
an opportunity for translational research. By collecting
pretreatment biopsies, we attempted to identify biomarkers that
could predict chemotherapy response, whereas collecting post-
treatment tissue samples allowed us to examine gene expression
changes in response to treatment. Recent studies have focused on
using DNA microarrays to identify gene expression patterns
predictive of chemotherapy response (Chang et al, 2003; Ayers
et al, 2004; Bertucci et al, 2004; Hannemann et al, 2005; Iwao-
Koizumi et al, 2005; Sørlie et al, 2006), and we performed similar
analyses here.
PATIENTS AND METHODS
Eligibility criteria
Female patients 18 years or older with a histopathological or
cytological diagnosis of breast carcinoma were eligible. Patients
with T3, T4, N2, or T2 tumours X3cm were included. No prior
treatments were permitted. Additional inclusion criteria were
Karnofsky performance status X70, adequate bone marrow
reserve and organ function (hepatic and renal), and normal left
ventricular ejection fraction (67±8%) by echocardiography.
Patients with inflammatory breast cancer, a second primary
malignancy, a previous cancer within the last 5 years, or active
cardiac disease not controlled by therapy and/or an infarction
within the preceding 6 months were excluded. Appropriate ethical
review boards approved the protocol, patients provided written
informed consent before enrolment, and the trial was conducted in
accordance with the Declaration of Helsinki and good clinical
practise standards.
Study design
The primary objective of this multicentre, open-label, non-
randomised, phase II study was to evaluate the pCR rate of
sequential neoadjuvant GemþDox followed by GemþCis in
patients with operable breast cancer. The secondary objectives of
the study were to characterise toxicity, to examine gene expression
profiles and identify biomarkers that might predict and/or
characterise chemotherapy response, and to determine survival
and progression-free survival rates after 5 years. Because patients
remain in follow-up at the time of this publication, time-to-event
parameters will be presented in a subsequent publication.
Treatment plan
Treatment consisted of four cycles (21 days) of gemcitabine
1200mgm
 2 plus doxorubicin 60mgm
 2 (GemþDox), four
cycles of gemcitabine 1000mgm
 2 plus cisplatin 70mgm
 2
(GemþCis), and surgery. Gemcitabine, doxorubicin, and cisplatin
were administered by intravenous infusion and cisplatin admin-
istration included standard hydration and antiemetic procedures.
Full supportive care, including antibiotics, antiemetics, and
granulocyte colony-stimulation factors, was administered as
clinically indicated.
We administered three sequences of GemþDox during cycle 1
and collected tumour biopsies after the first dose of treatment via
fine needle aspiration cytology to capture single-agent treatment
effects and potential changes in molecular profiles. The first 20
patients received gemcitabine on days 1 and 8 plus doxorubicin on
day 2 (Gem d1, 8; Dox d2). The next 20 patients received
gemcitabine on days 1 and 8 plus doxorubicin on day 1 (Gem d1, 8;
Dox d1). The remaining 25 patients received doxorubicin on day 1
plus gemcitabine on days 2 and 8 (Gem d2, 8; Dox d1). For cycles 2
through 4, all patients received Gem d1, 8 and Dox d1. For cycles 5
through 8, patients received gemcitabine on days 1 and 8 plus
cisplatin on day 1 (GemþCis).
Day-1 doses for gemcitabine, doxorubicin, or cisplatin were
delayed for 1 week if the absolute neutrophil count (ANC) was
o1.5 10
9l
 1 and/or platelets were o100 10
9l
 1. Subsequent
gemcitabine and cisplatin doses were decreased by 25% after any
of the following: febrile neutropenia, grade 4 neutropenia lasting
47 days, grade 4 thrombocytopenia lasting 43 days, Xgrade 2
bleeding with thrombocytopenia (any grade), or grade 3 non-
haematologic toxicities (except nausea/vomiting). Grade 4 non-
haematologic toxicities required either a 50% dose reduction of
gemcitabine and cisplatin or a delay. Cisplatin doses were reduced
by 50% for grade 2 peripheral neurotoxicity or creatinine clearance
between 35 and 49mlmin
 1; the cycle was delayed for grade 3 or
4 peripheral neurotoxicity or creatinine clearance o35mlmin
 1.
A decrease in ejection fraction below 45% or a net decrease
in ejection fraction X10% below baseline, or clinical congestive
heart failure required patient discontinuation.
Gemcitabine day-8 doses were reduced by 25% if the ANC was
between 0.5 and 0.99 10
9l
 1 or platelets were between 50 and
99 10
9l
 1. Gemcitabine day-8 doses were omitted if the ANC was
o0.5 10
9l
 1 and platelets were 450 10
9l
 1, or for any ANC
and platelets o50 10
9l
 1. Day-8 doses were reduced by 50% or
omitted for grade 3 non-haematologic toxicities (except nausea/
vomiting), and were omitted for grade 4 non-haematologic
toxicities (except nausea/vomiting). Patients who required either
a 6-week dose delay or three dose reductions were discontinued
from treatment.
The extent and type of surgery that followed chemotherapy
(breast conservation surgery or mastectomy with axillary lymph
node dissection) was guided by the tumour size, physician, and/or
patient decision. After surgery, patients who were oestrogen
receptor- and/or progesterone receptor-positive were treated with
tamoxifen.
Baseline and treatment assessments
Pretreatment biopsies (incisional) were taken for histopathology,
prognostic marker evaluation (hormone receptor and HER2), and
DNA microarray analysis. Hormone receptors (oestrogen receptor
or progesterone receptor) and HER2 status were determined by
immunohistochemistry. Two additional samples, one fine needle
aspiration cytology collected before treatment on day 2 of cycle 1
and one needle core biopsy collected at the end of cycle 4, were
collected for future correlative analyses.
Baseline radiological imaging studies (mammogram, abdominal
ultrasound, and chest x-ray) were performed. Clinical response,
evaluated by physical exam, was classified using the Southwest
Oncology Group criteria (Green and Weiss, 1992) before each cycle
for all patients who received at least one dose of chemotherapy.
Pathologic response was assessed using the Miller and Payne
classification system (Ogston et al, 2003), with a pCR defined as
grade 5. Specifically, a grade 5 designation is characterised as no
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smalignant cells in sections from the site of the previous tumour
and allows for the presence of ductal carcinoma in situ. The
pathologic response status was evaluated by a local pathologist and
an independent reviewer. All patients who had surgery after
chemotherapy were included in the assessment of pathologic
response.
Clinical laboratory tests (haematology and blood chemistries)
were performed at baseline, before the day-8 dose of each cycle,
within 4 days before the start of subsequent cycles, and on day 21
of cycle 8. All women who received at least one dose of
chemotherapy were assessed for safety before each cycle using
the National Cancer Institute Common Toxicity Criteria Scale,
version 2.0 (National Cancer Institute, 1999).
Statistical considerations
Potential clinical prognostic factors (age, menopausal status,
tumour size, clinical node status, hormone receptor status, and
HER2 status) were assessed individually for their association with
both clinical response and pCR using logistic regression analysis.
RNA isolation and microarray hybridisation
Pretreatment incisional biopsies were immediately placed into
RNAlater
s (Ambion, Foster City, CA, USA) and stored at  801C.
Total RNA was prepared from biopsies using Qiagen RNAeasy kits
(Qiagen, Valencia, CA, USA) and its quality was checked using an
Agilent Bioanalyzer (Agilent, Santa Clara, CA, USA). Samples with
X1mg of total RNA and discernable 18S and 28S peaks were used
for microarray analysis (46 of 65 patients). Total RNA was
amplified and labelled as previously described (Hu et al, 2005).
Microarray hybridisations were performed on Agilent Human 1A
(V2) microarrays using 2mg of Cy3-labelled common reference
sample (Novoradovskaya et al, 2004) and 2mg of Cy5-labelled
experimental sample. Microarrays were hybridised overnight,
washed, dried, and scanned as previously described (Hu et al,
2005). Microarray image files were analysed with GenePix Pro 4.1
(Molecular Devices, Sunnyvale, CA, USA) and loaded into the
UNC-CH Microarray Database (https://genome.unc.edu/), and are
available in the Gene Expression Omnibus (http://www.ncbi.nlm.-
nih.gov/geo) under the series numbers GSE8465.
Microarray analysis and prediction of response
Data from the microarray experiments were processed as
previously described (Hu et al, 2005). Briefly, genes that did not
have a signal intensity X30 in both channels for X70% of the
experiments were excluded. To predict response, the gene
expression data for the 46 pretreatment samples were analysed
using the following as ‘supervising parameters’: clinical complete
response (CR) after each cycle of chemotherapy (CR vs PR, SD, and
PD combined), overall clinical complete response (CR vs non-CR,
evaluated after the last successfully completed therapy cycle, not
necessarily cycle 8), pCR, and clinical ER status (included as a
positive control).
Four statistical classification methods were used to predict
chemotherapy response using the pretreatment gene expression
data: a k-nearest neighbour classifier (k-NN with k¼1, 3, 5, or 7)
with either Euclidean distance or one minus Spearman correlation
as the distance function and a Class Nearest Centroid (CNC)
classifier with either Euclidean distance or one minus Spearman
correlation as the distance function, as described previously
(Chung et al, 2004). To evaluate prediction accuracy, each of the
four classification methods underwent 10-fold cross validation
(CV); in each round of CV, each predictor using n genes (how the
n genes were selected is described below) was trained on 90% of
the samples and used to make predictions on the remaining 10%,
with this procedure repeated nine more times such that every
sample was ‘left out’ exactly once. The mean prediction accuracy
for the 10 iterations was recorded for each classification method
using n genes. Note that n was increased for subsequent rounds of
CV. For each response variable, the set of n genes that gave the
highest average prediction accuracy during CV was determined
and reported for each classification method (accuracies were
reported with associated binomial confidence intervals).
Each classification method required a gene/feature selection step
to identify genes associated with each ‘class’ (i.e., CR vs PRþSD).
For all four methods, we used a gene selection method described
by Dudoit et al (2002); the genes were identified in the training set
according to the ratio of between-class to within-class sums of
squares. The top n-ranked genes were used during each round of
CV. Because the number of cases in our study was relatively small
(n¼46), we did not break our data into training and test sets but
instead performed 10-fold CV using the four statistical classifica-
tion methods to avoid overfitting caused by using a single
classification method or fortuitous training and test set randomi-
sations.
RESULTS
Patient characteristics
Sixty-five Indian women enroled between February 2003 and
March 2004 at the All India Institute of Medical Sciences in New
Delhi, the Christian Medical College and Hospital in Vellore, and
the Hirabai Cowasji Jehangir Medical Research Institute, Jehangir
Hospital, in Pune. Table 1 shows baseline patient and disease
characteristics. Most patients had ductal breast cancer (61 of 65).
Patients generally had large tumours, with 84% of primary
tumours identified as T3 or larger, and the median size of the
largest baseline lesion was 30cm
2 (range, 7.8–85.8cm
2).
Treatment administration
Fifty-three patients had post-treatment surgery, but only 40 of
these completed all eight cycles of chemotherapy. Twenty-five
patients (38.5%) discontinued before completing eight cycles,
although 13 of these had surgery. Twelve of 25 patients who
discontinued stopped on or before cycle 4. Reasons for disconti-
nuing chemotherapy included: adverse event (5 of 25), death from
study drug toxicity (4 of 25), unrelated death (1 of 25), disease
progression (2 of 25), satisfactory response (9 of 25, and all but one of
these had surgery), and other patient decision (4 of 25). For the subset
of patients who discontinued without surgery (12 of 25), reasons for
discontinuation included death (5 of 12), adverse event (2 of 12), and
missing follow-up visits or other patient decision (5 of 12).
The median relative dose intensity was 97% for doxorubicin,
96% for gemcitabine in cycles 1 through 4, 86% for gemcitabine in
cycles 5 through 8, and 95% for cisplatin. There were 49 dose
reductions (37 gemcitabine, seven doxorubicin, and five cisplatin)
due to adverse events, with neutropenia (25 of 49) and febrile
neutropenia (15 of 49) being the most prevalent reasons for
adjustment. There were 34 gemcitabine dose omissions attributed
to adverse events, most of which were due to neutropenia (13 of
34), fatigue (6 of 34), or mucositis (3 of 34). Of the 33 cycle delays
attributed to adverse events, most were due to neutropenia,
leukopenia, or mucositis.
Clinical results
Efficacy Patient outcomes are summarised in Table 2. The overall
clinical response rate was 81.5% (with 22 CRs), and all of the
responders showed the first signs of response on or before cycle 4.
After completion of therapy, 35 patients had modified radical
mastectomy and 18 had breast conservation surgery. Of the 53
patients who had surgery, 13 (24.5%) showed a pCR.
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sPrognostic factor analyses conducted on all enroled patients
showed that age, menopausal status, hormone receptor status,
HER2 status, tumour size, and clinical node status were not
associated with either clinical response (CR or PR) or pCR.
Toxicity Although subgroup analyses of cohorts that had
alternate cycle-1 dosing sequences were not preplanned, unfore-
seen safety issues prompted a more detailed evaluation. Patients
who received Gem d1, d8 and Dox d2 during cycle 1 showed higher
rates of toxicity. This was unexpected since the three patient
cohorts received the same treatment schedule for GemþDox in
cycles 2 through 4 (Gem d1, 8; Dox d1) and for GemþCis in cycles
5 through 8. Supplementary Table 1 lists the incidence of toxicity
by cycle for each cycle-1 cohort. Eighty per cent of the CTC grade 3
or 4 (G3/4) toxicities seen in cycle 1 occurred in the patients who
received Gem d1, 8 and Dox d2 (33 of 41). The most common
cycle-1 toxicities for this cohort were febrile neutropenia or
infection with G3/4 neutropenia in 35% of patients (three patients
with G3 and four patients with G4) and G3/4 vomiting in 25% of
patients (three patients with G3 and two patients with G4). G3
dehydration (3 of 20), G3 diarrhoea (3 of 20), and G3
thrombocytopenia (3 of 20) each occurred in 15% of patients in
cycle 1.
A summary of G3/4 toxicity reported throughout the entire
study is shown in Table 3. Neutropenia was prevalent in all three
cohorts, with an incidence of 23.1% for grade 3 (15 of 65) and
18.5% (12 of 65) for grade 4. Both G3 mucositis and G3/4 anaemia
were somewhat more prevalent in the Gem d1, 8 and Dox d2
cohort, but the incidence for each cohort was no higher at the
beginning than at the end of the study.
Five patients died on-study and four deaths were attributed to
treatment-related toxicity. These deaths did not appear to be
directly related to the alternate dosing schedules used in cycle 1.
For one patient, the doses for GemþDox were incorrectly
calculated in cycle 1 such that the patient received a 20% higher
dose for gemcitabine and a 25% higher dose for doxorubicin. The
patient was hospitalised for neutropenic sepsis several days after
the day-8 dose of gemcitabine and died. The second patient
experienced neutropenia with infection, hypoglycemia, and
anaemia during cycle 3 and died of cardiac arrest. The third
patient died after 8 days of hospitalisation in cycle 8 for
convulsions, vomiting, diarrhoea, and neutropenic sepsis. The
fourth patient was hospitalised during cycle 8 for severe diarrhoea
and died of cardiac arrest secondary to severe hypokalemia. A fifth
patient died of acute myocardial infarction, which was not
attributed to study treatment.
Table 1 Baseline patient and disease characteristics
Gem d1,8; Dox d2
a
(n¼20)
Gem d1,8; Dox d1
a
(n¼20)
Gem d2,8; Dox d1
a
(n¼25)
All
(n¼65)
b
Correlative Subset
(n¼46)
c
Median age (range), years 45.5 (35–65) 45.5 (31–69) 49 (31–70) 46 (31–70) 48 (32–69)
Karnofsky performance status, n (%)
90 19 (95.0) 17 (85.0) 20 (80.0) 56 (86.2) 40 (87.0)
100 1 (5.0) 3 (15.0) 5 (20.0) 9 (13.8) 6 (13.0)
Menstruation status, n (%)
Premenopausal 8 (40.0) 10 (50.0) 11 (44.0) 29 (44.6) 19 (41.3)
Postmenopausal 12 (60.0) 10 (50.0) 14 (56.0) 36 (55.4) 27 (58.7)
Disease stage, n (%)
IIA 2 (10.0) 0 1 (4.0) 3 (4.6) 2 (4.3)
IIB 10 (50.0) 9 (45.0) 11 (44.0) 30 (46.2) 21 (45.7)
IIIA 4 (20.0) 6 (30.0) 8 (32.0) 18 (27.7) 11 (23.9)
IIIB 4 (20.0) 5 (25.0) 5 (20.0) 14 (21.5) 12 (26.1)
Estrogen receptor/progesterone receptor status, n (%)
+/+ 4 (20.0) 10 (50.0) 13 (52.0) 27 (41.5) 19 (41.3)
+/  4 (20.0) 3 (15.0) 1 (4.0) 8 (12.3) 5 (10.9)
 /+ 1 (5.0) 0 2 (8.0) 3 (4.6) 3 (6.5)
 /  11 (55.0) 6 (30.0) 8 (32.0) 25 (38.5) 18 (39.1)
HER2-neu expression, n (%)
0, or 1+ or 2+ 7 (35.0) 13 (65.0) 17 (68.0) 37 (56.9) 27 (58.7)
3+ 9 (45.0) 5 (25.0) 5 (20.0) 19 (29.2) 12 (26.1)
Not detected 4 (20.0) 1 (5.0) 2 (8.0) 7 (10.8) 6 (13.0)
d¼day; Dox¼doxorubicin; Gem¼gemcitabine; y¼years.
aCohort defined by cycle-1 schedule of gemcitabine plus doxorubicin.
bTotal N equals 63 for hormone receptor
status and HER2-neu expression due to insufficient sample quantity. Note that 12 of 63 patients in the trial and 10 of 45 in the correlative subset were negative for receptor
status and HER2 (i.e., HER2 was either not detected or 0).
cCorrelative subset includes patients with pretreatment microarray data. Correlative subset equals 45 for receptor
status and HER2-neu expression.
Table 2 Patient outcomes after neoadjuvant chemotherapy
Correlative subset
a
(n¼46)
All
(n¼65)
Overall clinical response (CR+PR)
b, n (%) 37 (80.4) 53 (81.5)
CR 16 (34.8) 22 (33.8)
PR 21 (45.7) 31 (47.7)
SD 5 (10.9) 7 (10.8)
Not determined 4 (8.7) 5 (7.7)
Surgery, n (%) 37 (80.4) 53 (81.5)
Pathologic complete response (pCR)
c, n (%) 13 (35.1) 13 (24.5)
CR¼complete response; PR¼partial response; SD¼stable disease.
aCorrelative
subset includes patients with pretreatment microarray data. Twenty-eight of these
patients completed all eight cycles of chemotherapy and had surgery.
bSWOG overall
best study response rates were based on all enroled patients who received at least
one dose of chemotherapy. SWOG best response was not determined for patients
who discontinued treatment after one or two cycles.
cThe pCR rate was based on
the total number of patients who had posttreatment pathology (i.e., 37 for the
correlative subset and 53 for all patients).
Molecular profiles for gemcitabine-based chemotherapy
PK Julka et al
1330
British Journal of Cancer (2008) 98(8), 1327–1335 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sGene expression analysis and prediction of response
Analysis of tumour samples using the breast intrinsic gene set We
assayed 46 pretreatment biopsy samples using Agilent human
microarrays covering over 17000 genes (19 of 65 samples failed to
give usable RNA). To investigate the expression data, we first
hierarchically clustered (Eisen et al, 1998) the 46 pretreatment
samples using a 1300-gene breast intrinsic gene set developed by
Hu et al (2006), which can identify the intrinsic tumour subtypes
(luminal A, luminal B, basal-like, HER2þ/ER  and normal
breast-like) that show significant differences in patient outcome
(Sørlie et al, 2001, 2003). The main intrinsic subtypes of luminal,
basal-like, and HER2þ/ER  (Supplementary Figure 1) were
identifiable in this Indian patient dataset, which is consistent with
previous studies showing that the breast tumour intrinsic subtypes
are conserved across ethnic groups (Yu et al, 2004; Carey et al,
2006).
Association of response with breast intrinsic subtype We exam-
ined response rates within the breast intrinsic subtypes as assigned
from Supplementary Figure 1. The basal-like subtype had the
highest pCR rate (7 of 14, 50%), which is consistent with findings
of previous studies (Rouzier et al, 2005; Carey et al, 2007), and
luminal tumours had the lowest pCR rate (3 of 15, 20%), but the
association was not statistically significant (Table 4, P¼0.23).
Prediction of neoadjuvant chemotherapy response We performed
supervised analyses on the pretreatment gene expression data and
determined the 10-fold CV error rates for predicting (1) pCR, (2)
overall clinical complete response (CR vs non-CR), and (3) CR vs
non-CR after each cycle (results presented here are only for CR vs
non-CR after cycle 8). Supplementary Tables 2 through 4 show that
the 10-fold CV analyses using the CNC and k-NN classification
methods yielded gene expression profiles/predictors that accu-
rately classified tumours according to (1) pCR vs no pCR (73%
(95% CI: 0.57–0.85)  78% [95% CI: 0.63–0.89] accuracy), (2)
overall CR vs non-CR (83% [95% CI: 0.69–0.92]  88% [95% CI:
0.75–0.95] accuracy), and (3) CR vs non-CR after cycle 8 (75%
[95% CI: 0.57–0.87]  89% [95% CI: 0.73–0.96] accuracy) for the
46 tumour samples that yielded pretreatment microarray data.
Each of the four prediction methods achieved similar accuracies
when used to predict a given response variable. Prediction of ER
status was included as a positive control for our gene expression-
based predictors; it represents the upper threshold of how good a
predictor can be (87% [95% CI: 0.74–0.94]  89% [95% CI: 0.76–
0.95] accuracy) on this dataset, providing a benchmark against
which the chemotherapy response predictors can be judged
(Supplementary Table 5).
Using the gene lists identified in the 10-fold CV analysis as being
predictive of pCR (Supplementary Table 2, Euclidian Nearest
Centroid), we hierarchically clustered (Eisen et al, 1998) the
pretreatment biopsy samples to better understand the predictive
genes and their relationships to each other. Figure 1 shows the
hierarchical clustering of tumours using the 94-gene set predictive
of pCR (76% accuracy in the 10-fold CV analysis). (Note: the
classification of samples into clusters and the associated accuracies
shown in Figures 1 and 2 and Supplementary Figure 2 are different
from those observed in the 10-fold CV analysis and are for
Table 3 Incidence of CTC grade 3 and grade 4 haematologic and non-haematologic toxicity by cohort
a
Gem d1,8; Dox d2 (n¼20) Gem d1,8; Dox d1 (n¼20) Gem d2,8; Dox d1 (n¼25)
Toxicity
b Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4
Anaemia 5 3 1 1 1 1
Neutropenia 5 7 6 3 4 2
Leukopenia 2 0 1 0 0 0
Thrombocytopenia 4 1 2 0 0 1
ALT (SGPT) 1 0 0 0 0 1
Hypokalemia 1 3 0 1 0 0
Hyponatremia 1 0 0 1 1 0
Hypernatremia 0 1 0 0 0 0
Hypoglycemia 0 0 0 0 0 1
Fatigue 2 0 1 1 1 0
Oral/pharyngeal mucositis 5 1 0 0 2 0
Dehydration 5 0 0 0 1 0
Vomiting 3 3 0 0 1 0
Diarrhoea 4 0 1 0 0 0
Febrile neutropenia 3 4 0 0 0 0
Infection with grade 3/4 neutropenia 1 1 0 2 0 1
ALT¼alanine aminotransferase; d¼day; Dox¼doxorubicin; Gem¼gemcitabine; SGPT¼serum glutamic pyruvic transaminase.
aCohort defined by cycle-1 schedule of
gemcitabine plus doxorubicin.
bToxicities were graded according to Common Toxicity Criteria (version 2.0) and listed according to maximum grade reported. Includes all
toxicities recorded as grade 4 and all grade 3 toxicities that occurred in 42 patients.
Table 4 Association between response designation and tumour intrinsic subtype for the correlative subset (n¼46)
a
Pathologic Complete Response
b Clinical Response Designation
b
Intrinsic subtype Yes No CR PR SD
Luminal (A+B) 3 12 7 8 1
HER2+/ER  34 1 6 1
Basal-like 7 7 7 7 3
aCorrelative subset includes patients with pretreatment microarray data.
bClinical response was not determined for four patients who discontinued after one or two cycles. One
patient with a CR was not included in the table because classification was normal breast-like.
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sillustrative purposes only.) Using the program EASE (Hosack et al,
2003), the Gene Ontology (GO) (http://www.geneontology.org)
categories ‘nucleotide/nucleic acid metabolism’ and ‘DNA meta-
bolism’ were over-represented relative to chance in the gene set
highly expressed in tumours with pCR (Figure 1, top gene
dendrogram branch).
Figure 2 shows the hierarchical clustering of tumours using the
71-gene set predictive of clinical response at treatment cycle 8
(86% accuracy in the 10-fold CV analysis). According to EASE, the
GO categories ‘nucleotide/nucleic acid metabolism,’ ‘RNA meta-
bolism,’ ‘DNA repair,’ and ‘response to stress’ were over-
represented relative to chance in the gene set highly expressed in
tumours with CR at cycle 8 (Figure 2, bottom gene dendrogram
branch). Interestingly, the complete responders at cycle 8 showed
high expression of NUDT2, which is not only involved in
nucleotide metabolism but may also promote apoptosis (Vartanian
 Eyes absent homolog 2 Drosophila  U71207 
 Similar to CG6405 gene product  NM_145269 
 Sideroflexin 2  AF462052 
 Suppressor of potassium transport defect 3  NM_030813 
 Hypothetical protein MGC41816  NM_016466 
 Polymerase RNA III DNA directed polypeptide H 22.9kD  NM_138338 
 Px19-like protein  NM_013237 
 RNA binding motif protein 4  NM_002896 
 PP3111 protein  NM_022156 
 Nuclear protein localization 4  NM_017921 
 Nuclear protein localization 4  AK000664 
 Fructosamine-3-kinase-related protein  AK022233 
 R3H domain binds single-stranded nucleic acids containing  D21852 
 Chromosome 3 open reading frame 10  NM_018462 
 R3H domain binds single-stranded nucleic acids containing  NM_015361 
 START domain containing 7  NM_020151 
 KIAA1627 protein  NM_020961 
 Chromosome 9 open reading frame 40  NM_017998 
 Centromere protein E, 312kDa  NM_001813 
 CDC7 cell division cycle 7 S. cerevisiae  NM_003503 
 RAD54-like S. cerevisiae  NM_003579 
 Cell division cycle associated 8  NM_018101 
 Kinetochore associated 2  NM_006101 
 Ubiquitin-like, containing PHD and RING finger domains, 1  NM_013282 
 Choline kinase alpha  D10704 
OLIGO
 Receptor-interacting factor 1  NM_018372 
OLIGO
 Chromosome 1 open reading frame 33  AK027569 
 Hypothetical protein MGC33488  NM_138350 
 Gap junction protein, alpha 12, 47kDa  NM_020435 
 Hypothetical protein LOC127253 BC009514 
 Processing of precursor 1, ribonuclease P/MRP NM_015029 
 RNA-binding region RNP1, RRM containing 1  BC018711 
 F-box and leucine-rich repeat protein 11  AB023221 
 NADH dehydrogenase ubiquinone flavoprotein 1, 51kDa  NM_007103 
 Transforming, acidic coiled-coil containing protein 3  NM_006342 
 RecQ protein-like 4  NM_004260 
 Protease, serine, 15  NM_004793 
 Phosphodiesterase 7A  U67932 
OLIGO
 Zinc finger and SCAN domain containing 5  NM_024303 
 NM_031214 
 GALNTL1 AB032956 
 8-oxoguanine DNA glycosylase  NM_016821 
 Zinc finger protein 34 KOX 32  BC004480 
 Small proline-rich protein 3  NM_005416 
 UDP-glucose ceramide glucosyltransferase-like 2  NM_020121 
 Sulfatase modifying factor 2  NM_015411 
 Ras-related GTP binding B  X90530 
 Hypothetical protein MGC39662  NM_152394 
OLIGO
 Coenzyme Q6 homolog yeast  AF132944 
 Four and a half LIM domains 1  U29538 
 S75308 
 Dnaj-like protein  AK056937 
 LEM domain containing 3  AF112299 
 Glutamine-fructose-6-phosphate transaminase 1  M90516 
 Chromosome 20 open reading frame 13  NM_017714 
 Presenilin 1 Alzheimer disease 3  NM_007319 
 Hypothetical protein MGC33302  NM_152778 
 Interleukin 11 receptor, alpha  NM_147162 
 Neural cell adhesion molecule 1  S71824 
 NM_017624 
 Keratin associated protein 3-1  NM_031958 
 Kinesin family member 1A  NM_004321 
 Microcephaly, primary autosomal recessive 1  AK022909 
 Taste receptor, type 2, member 8  NM_023918 
 Triggering receptor expressed on myeloid cells 4  BC025395 
 KIAA0828 protein  AK025372 
 Pleckstrin homology domain containing, family C member 1  BC017327 
 NIMA never in mitosis gene a-related kinase 7  NM_133494 
 AF218313 
 Cyclin M3  NM_017623 
 Ubiquitin-conjugating enzyme E2 G1 NM_003342 
 Ring finger protein 14  AF060544 
 Guanine nucleotide binding protein G protein, alpha 14  NM_004297 
 DnaJ Hsp40 homolog, subfamily D, member 1  NM_013238 
 Transmembrane channel-like 5  NM_024780 
 RAB GTPase activating protein 1-like  NM_014857 
 ERBB3  NM_001982 
 Zinc finger protein 554  NM_152303 
 Islet cell autoantigen 1, 69kDa  NM_004968 
 Chromosome 7 open reading frame 27  BC007209 
 MGC16028 similar to RIKEN cDNA 1700019E19 gene  NM_052873 
 CAMP responsive element binding protein 3-like 4  NM_130898 
 SEC15-like 1 S. cerevisiae  NM_019053 
 Glioblastoma amplified sequence  BC030821 
 Solute carrier family 39 zinc transporter, member 9  NM_018375 
 Chromosome 1 open reading frame 26  AF288392 
 GTP binding protein 6 putative  Y14391 
 Hemoglobin, alpha 1  NM_000558 
 OLIGO 
CD99 antigen NM_002414
1:1 >1. 2 >2.4 >1.2 >2.4
Relative to median expression
Figure 1 Hierarchical cluster analysis of pretreatment tumour samples using the 94-gene set predictive of pCR. Blue and yellow dendrogram branches
indicate tumours with pCR and no pCR, respectively.
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set al, 1999; Swarbrick et al, 2005). Supplementary Figure 2 shows
the hierarchical clustering of tumours using the 66-gene set
predictive of overall CR (88% accuracy in the 10-fold CV analysis).
Interestingly, the responders represented in Supplementary Figure
2 showed high expression of FADD, which also promotes apoptosis
(Chinnaiyan et al, 1995).
DISCUSSION
This phase II study of sequential GemþDox and GemþCis as
neoadjuvant therapy in breast cancer showed strong activity
(an overall clinical response rate of 81.5% and a pCR rate of
24.5%), but also revealed unforeseen safety issues related to the
administration of an alternate schedule of GemþDox in cycle 1.
To facilitate tissue sampling for biomarker analyses in the present
trial, we used three dosing sequences in cycle 1 only. Dosing
sequences were Gem d1, d8 and Dox d2 or Gem d2, d8 and Dox d1
in two of the three patient cohorts, and the more standard dosing
sequence of Gem d1, d8 and Dox d1 for the third cohort in cycle 1
and for all patients in cycles 2 through 4. Patients who received
Gem d1, d8 and Dox d2 during cycle 1 showed higher rates of
toxicity during cycle 1 (Supplementary Table 1), with febrile
neutropenia, neutropenia with infection, and vomiting being the
most prevalent toxicities. Toxicity profiles for the other two
cohorts were more manageable (Table 3), and the incidence and
types of adverse events were similar to those in previous phase II
studies of gemcitabine plus doxorubicin in patients with breast
 Hydroxyprostaglandin dehydrogenase 15-NAD  X82460 
 Placenta-specific 2  BC047562 
 Homer homolog 1 Drosophila  NM_004272 
 Glycyl-tRNA synthetase  BC007722 
 Solute carrier family 35, member F2  NM_017515 
 Defensin, beta 1  NM_005218 
 Pim-1 oncogene  BC020224 
 Malignant fibrous histiocytoma amplified sequence 1  NM_004225 
 Solute carrier family 38, member 4  AF193836 
 Hypothetical protein DKFZp434I099  AL136907 
 GLIS family zinc finger 2  AF325914 
 Crystallin, gamma D  NM_006891 
 Integrin beta 1 binding protein melusin 2  NM_012278 
 Signal transducer and activator of transcription 2, 113kDa  NM_005419 
 Zinc finger protein 597  NM_152457 
 Hypothetical protein LOC51057  NM_015910 
 Wingless-type MMTV integration site family, member 1  NM_005430 
 Hypothetical protein FLJ25369  NM_152670 
 OLIGO 
 Protein kinase, lysine deficient 1  NM_018979 
 Protein kinase NYD-SP25  AY032877 
 Topoisomerase DNA III alpha  U43431 
 H2A histone family, member Y2  NM_018649 
 Myosin XVB, pseudogene  AK026339 
 Interleukin 1 receptor antagonist  X52015 
 Hypothetical protein BC013113  NM_138461 
 Angiopoietin-like 4  AF153606 
 Sulfotransferase family, cytosolic, 2B, member 1  U92315 
 BTG family, member 2  NM_006763 
 Suppressor of Ty 4 homolog 1 S. cerevisiae  NM_003168 
 Tubulin, alpha-like 3  NM_024803 
 Kinesin family member 23  NM_138555 
 Hypothetical protein MGC33488  NM_138350 
 Forkhead box J2  NM_018416 
 HCF-binding transcription factor Zhangfei  AF039942 
 PRP3 pre-mRNA processing factor 3 homolog yeast  AF016370 
 Protein inhibitor of activated STAT, 3  NM_006099 
 Growth hormone regulated TBC protein 1  AK026127 
 Zinc finger protein 24 KOX 17  BC016801 
 Catenin cadherin-associated protein, alpha-like 1  NM_003798 
 Chromosome 20 open reading frame 19  NM_018474 
 Nuclear ubiquitous casein kinase and cyclin-dependent kinase substrate  BC000805 
 Nudix nucleoside diphosphate linked moiety X-type motif 2  NM_001161 
 NM_005758 
 Small nuclear ribonucleoprotein polypeptide E  NM_003094 
 Mitochondrial ribosomal protein L51  NM_016497 
 COBW domain containing 1  AF257330 
 Activating signal cointegrator 1 complex subunit 3-like 1  NM_014014 
 Ubiquitin specific protease 32  NM_032582 
 Methyltransferase like 2  AK002212 
 KIAA1287 protein  NM_020748 
 NADPH dehydrogenase, quinone 2  NM_000904 
 Replication protein A1, 70kDa  NM_002945 
 Histidyl-tRNA synthetase  AK000498 
 M16707 
 Serine threonine kinase 39 STE20/SPS1 homolog, yeast  NM_013233 
 I_957887 
 Histone 1, H4f  NM_003540 
 Histone 1, H4h  NM_003543 
 OLIGO 
 DNA replication complex GINS protein PSF2  NM_016095 
 Kinetochore protein Spc25  NM_020675 
 NM_152368 
 Retinoblastoma binding protein 8  NM_002894 
 Poly ADP-ribose polymerase family, member 2  NM_005484 
 RAD51 homolog C S. cerevisiae  NM_002876 
 Microsomal glutathione S-transferase 3  NM_004528 
 Small nuclear ribonucleoprotein polypeptide F  NM_003095 
 Eyes absent homolog 2 Drosophila  U71207 
 Eyes absent homolog 2 Drosophila  NM_172113 
AB014535
1:1 >1. 2 >2.4 >1.2 >2.4
Relative to median expression
Figure 2 Hierarchical cluster analysis of pretreatment tumour samples using the 71-gene set predictive of clinical response after eight treatment cycles.
Blue and yellow dendrogram branches indicate complete and non-complete responders, respectively.
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scancer (Pe ´rez-Manga et al, 2000; Gomez et al, 2001; El Serafy et al,
2003; Bensalem and Bouzid, 2006).
Although several different dosing regimens of GemþDox were
applied in previous studies, they were all similar in that
gemcitabine and doxorubicin were both given on day 1 and, in
some cases, were given together again on day 8 (Pe ´rez-Manga et al,
2000; Gomez et al, 2001; El Serafy et al, 2003; Bensalem and
Bouzid, 2006). In these previous studies, haematologic toxicities
were the most common, but alopecia and mucositis were also
prevalent. We know of no other studies that have evaluated the
administration of gemcitabine and doxorubicin sequentially on
days 1 and 2, and these results suggest that this schedule induces
unacceptable toxicity. The number of treatment-related deaths was
also high in this study, but the affected patients were not
disproportionately associated with any single cohort. The details
of each case were evaluated thoroughly, and we were unable to
identify unifying characteristics that indicated why these indivi-
duals were more vulnerable to the serious side effects of
chemotherapy. Notably, while the standard GemþDox dose
schedule produced a toxicity profile that was similar to previous
studies with GemþDox, the toxic death rate was higher than that
in previous trials (Pe ´rez-Manga et al, 2000; Gomez et al, 2001;
El Serafy et al, 2003; Bensalem and Bouzid, 2006). These events
highlight the need for appropriate patient education, careful
screening, and the use of additional supportive services in
developing countries like India, especially in areas where health-
care access may be limited.
The identification of molecular predictors of patient outcomes
will help us design safer and more effective regimens that are
tailored to individual patients. In the present study, we determined
that pretreatment gene expression patterns could predict response
to gemcitabine-containing neoadjuvant therapy. The accuracy
rates and associated confidence intervals achieved were encoura-
ging and similar to those achieved by predictors developed for
other neoadjuvant regimens (Chang et al, 2003; Ayers et al, 2004).
pCR is strongly correlated with improved long-term disease-free
and overall survival (Fisher et al, 1998; Kuerer et al, 1999;
Wolmark et al, 2001). There is evidence that clinical complete
response at the end of neoadjuvant chemotherapy is also
correlated with improved long-term survival (Ferrie `re et al, 1998;
Chang et al, 1999; Pierga et al, 2003; Cleator et al, 2005). Thus, the
gene expression-based predictors obtained in this study for pCR,
overall clinical complete response, and clinical complete response
after cycle 8 have the potential to be clinically useful if further
validated. As might be expected from gemcitabine’s mechanism of
action, nucleotide metabolism signatures were found to be
associated with response.
To conclude, sequential neoadjuvant gemcitabine plus doxor-
ubicin followed by gemcitabine plus cisplatin was effective for
downstaging large breast tumours in patients with operable breast
cancer, thereby improving treatment options for patients who
desired breast conservation surgery instead of mastectomy. Future
results for overall and disease-free survival will determine if these
high response rates will translate into improved long-term efficacy.
Significant toxicity was observed in a subgroup of patients who
received Gem d1, d8 and Dox d2, and this dosing sequence is not
recommended. The gene expression-based predictors identified here
may provide a method for selecting patients most likely to benefit
from gemcitabine-containing neoadjuvant therapy and, thus,
warrant further validation using additional datasets as they emerge.
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